Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11054MR)

This product GTTS-WQ11054MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11054MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3075MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ2263MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ9716MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ66MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15016MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ11333MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ9854MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA K7153A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW